Donate
Back to Clinical Trials
Back to Clinical Trials

Brief Title: LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors

INTRODUCTION

  • Org Study ID: LOXO-ENC-23001
  • Secondary ID: N/A
  • NCT ID: NCT06238479
  • Sponsor: Eli Lilly and Company

BRIEF SUMMARY

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

DETAILED DESCRIPTION

This is a Phase 1a/1b multicenter, open-label study in participants with advanced or metastatic solid tumor malignancies known to express Nectin 4. This study is comprised of two phases: Dose Escalation and Dose Optimization (1a), and Dose expansion (1b). Phase 1a will assess the safety, tolerability, and pharmacokinetics of LY4101174 to determine the recommended phase 2 dose (RP2D)/optimal dose. Phase 1b will evaluate efficacy and safety of LY4101174 at the RP2D/optimal dose in 7 expansion cohorts based on tumor type and/or treatment history.

  • Overall Status
    Recruiting
  • Start Date
    March 5, 2024
  • Phase
    Phase 1
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

  • Metastatic Solid Tumor
  • Recurrent Solid Tumor
  • Advanced Solid Tumor
  • Urinary Bladder Neoplasm
  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Esophageal Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Prostate Cancer
  • Renal Pelvis Cancer
  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
* Have one of the following solid tumor cancers:
* Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer

- * Cohort A2/B1/B2: urothelial carcinoma

- * Cohort C1: triple negative breast cancer

- * Cohort C2: non-small cell lung cancer

- * Cohort C3: ovarian or fallopian tube cancer

- * Cohort C4: cervical cancer

- * Cohort C5: head and neck squamous cell carcinoma

- * Prior Systemic Therapy Criteria:
* Cohort A1/C1-5: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies

- * Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.

- * Prior enfortumab vedotin specific requirements:
* Cohorts A1/A2/C1-5: prior treatment with enfortumab vedotin is allowed, but not required

- * Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting

- * Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.

- * Measurability of disease
* Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)

- * Cohorts A2, B1, B2, C1-5: measurable disease required as defined by RECIST v1.1
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- * Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations
Exclusion Criteria:
* Individual with known or suspected uncontrolled CNS metastases

- * Individual with uncontrolled hypercalcemia

- * Individual with uncontrolled diabetes

- * Individual with evidence of corneal keratopathy or history of corneal transplant

- * Any serious unresolved toxicities from prior therapy

- * Significant cardiovascular disease

- * Current of history of intestinal obstruction in the previous 3 months

- * Recent thromboembolic event or bleeding disorder

- * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms

- * History of pneumonitis/interstitial lung disease

- * History of Grade ≥3 skin toxicity when receiving enfortumab vedotin

- * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Xiaojian (Thomas) Xu

Role: Study Director

Affiliation: Loxo Oncology, Inc.

Overall Contact

Name: Patient Advocacy

Phone: 855-569-6305

Email: clinicaltrials@loxooncology.com

LOCATION

Facility Status Contact
Facility: Massachusetts General Hospital
Boston, Massachusetts 02114
United States 		Status: Recruiting Contact: N/A
Facility: Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York 10016
United States 		Status: Recruiting Contact: N/A
Facility: South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas 78229-3307
United States 		Status: Recruiting Contact: N/A

Read Our Stories